Next Article in Journal
Economical Analysis of Different Clinical Approaches in Pre-Viability Amniorrhexis—A Case Series
Next Article in Special Issue
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives
Previous Article in Journal
Repeat Lumbar Puncture: CSF Lactic Acid Levels are Predictive of Cure with Acute Bacterial Meningitis
Previous Article in Special Issue
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline
J. Clin. Med. 2014, 3(1), 1-24; doi:10.3390/jcm3010001
Review

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice

1,2
, 2,3
 and 1,2,*
Received: 9 November 2013; in revised form: 11 December 2013 / Accepted: 16 December 2013 / Published: 9 January 2014
(This article belongs to the Special Issue Prevention and Treatment of Bone Metastases from Breast Cancer)
View Full-Text   |   Download PDF [732 KB, uploaded 9 January 2014]   |   Browse Figures
Abstract: Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer are associated with skeletal-related events (SREs) including pathological fractures, spinal cord compression, surgery and radiotherapy to bone, as well as bone pain and hypercalcemia, leading to impaired mobility and reduced quality of life. Greater understanding of the pathophysiology of bone metastases has led to the discovery and clinical utility of bone-targeted agents such as bisphosphonates and the receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, denosumab. Both are now a routine part of the treatment of breast cancer bone metastases to reduce SREs. With regards to prevention, there is no evidence that oral bisphosphonates can prevent bone metastases in advanced breast cancer without skeletal involvement. Several phase III clinical trials have evaluated bisphosphonates as adjuvant therapy in early breast cancer to prevent bone metastases. The current published data do not support the routine use of bisphosphonates in unselected patients with early breast cancer for metastasis prevention. However, significant benefit of adjuvant bisphosphonates has been consistently observed in the postmenopausal or ovarian suppression subgroup across multiple clinical trials, which raises the hypothesis that its greatest anti-tumor effect is in a low estrogen microenvironment. An individual patient data meta-analysis will be required to confirm survival benefit in this setting. This review summarizes the key evidence for current clinical practice and future directions.
Keywords: breast cancer; bone metastases; bisphosphonates; denosumab; skeletal-related events; adjuvant; randomized controlled trials; meta-analysis breast cancer; bone metastases; bisphosphonates; denosumab; skeletal-related events; adjuvant; randomized controlled trials; meta-analysis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Li, B.T.; Wong, M.H.; Pavlakis, N. Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. J. Clin. Med. 2014, 3, 1-24.

AMA Style

Li BT, Wong MH, Pavlakis N. Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. Journal of Clinical Medicine. 2014; 3(1):1-24.

Chicago/Turabian Style

Li, Bob T.; Wong, Matthew H.; Pavlakis, Nick. 2014. "Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice." J. Clin. Med. 3, no. 1: 1-24.


J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert